Linical Co., Ltd. secured a large order worth 20.4 million USD from a U.S. biotech company. The contract delay was caused by partial U.S. government shutdowns and reduced FDA operations; the impact on the fiscal year ending March 2027 has been incorporated into the outlook announced in May 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2183","jir_company_name":"Linical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-09","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/2183-20261009-01.pdf","jir_short_summary":"Linical Co., Ltd. secured a large order worth 20.4 million USD from a U.S. biotech company. The contract delay was caused by partial U.S. government shutdowns and reduced FDA operations; the impact on the fiscal year ending March 2027 has been incorporated into the outlook announced in May 2026.","jir_summary":"### Overview of the Large Order\nThis matter concerns a large order from a U.S. biotech company. The cause of the contract delay is attributable to past partial closures of U.S. government agencies and a reduction in FDA operations. Order activity in the U.S. continues to trend upward, and the company intends to proactively pursue further order acquisition. The order amount is 20.4 million USD (3,212 million yen); details are as stated.\n\n### Financial Impact and Outlook\nIt is stated that the impact on results for the fiscal year ending March 2027 has been incorporated into the earnings guidance announced on May 15, 2026. An exchange rate for JPY\/USD on the acquisition date is provided as reference, but a detailed breakdown of the impact on financial results is unknown.","jir_financial_highlights":"Order Amount: 20.4 million USD (3,212 million yen) (Unknown)","jir_category":"","jir_hashtags":"#Linical, #LargeOrder","jir_key_figures":"Order Amount: 20.4 million USD (3,212 million yen)\nCounterparty: U.S. biotech company\nTiming of Impact: Impact on the fiscal year ending March 2027 has been incorporated into the earnings guidance","jir_meta_title":"Linical Co., Ltd. Secures Large Order | 20.4 million USD, Impact Incorporated into FY2027 Outlook","jir_meta_description":"Linical Co., Ltd. has secured a large order of 20.4 million USD from a U.S. biotech company. The impact on the fiscal year ending March 2027 has been incorporated into the outlook announced in May 2026. Key points including future order trends and exchange rate information are summarized.","jir_og_title":"Linical Co., Ltd. Secures Large Order | 20.4 million USD, Impact Incorporated","jir_og_description":"Secured a large order from a U.S. biotech company. The background of the contract delay, future order prospects, and that the impact on results has been incorporated into the outlook are explained.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59407,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-128695","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n